Project

CLL13-TRIAL OF THE GCLLSG IN COOPERATION WITH HOVON, NORDIC CLL STUDY GROUP AND SAKK (THE GA101 IBRUTINIB ABT101 (GAIA) TRIAL): A PHASE 3 MULTICENTER, RANDOMIZED, PROSPECTIVE, OPEN-LABEL TRIAL OF STANDARD CHEMOIMMUNOTHERAPY (FCR/BR) VERSUS RITUXIMAB PLUS VENETOCLAX (RVE) VERSUS OBINUTUZUMAB (GA101) PLUS VENETOCLAX (GVE) VERSUS OBINUTUZUMAB PLUS IBRUTINIB PLUS VENETOCLAX (GIVE) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL(17P) OR TP53 MUTATION

Automatically Closed · 2017 until 2024

RSS